{"result": "(\"entity\"<|>HIPO-NATREMIA<|>EVENT<|>Hipo-natremia refers to a condition characterized by low sodium levels in the blood, which can be caused by various factors including fluid imbalance and hormonal issues.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is a condition where excess ADH leads to water retention and dilutional hyponatremia.)\n##\n(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is a medication used to treat hyponatremia associated with SIADH by promoting water excretion.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Artificial nutrition refers to the provision of nutrients through means other than oral intake, often used in patients who cannot eat normally.)\n##\n(\"entity\"<|>FURST FORMULA<|>ORGANIZATION<|>The Furst formula is a method used to calculate sodium and potassium levels in patients undergoing treatment for hyponatremia.)\n##\n(\"entity\"<|>FUROSEMIDA<|>ORGANIZATION<|>Furosemide is a diuretic medication used to help reduce fluid retention and treat conditions like hypertension and edema.)\n##\n(\"entity\"<|>HIPOALDOSTERONISMO<|>EVENT<|>Hypoaldosteronism is a condition characterized by insufficient production of aldosterone, leading to imbalances in sodium and potassium levels.)\n##\n(\"entity\"<|>INSUFICIENCIA SUPRARRENAL<|>EVENT<|>Adrenal insufficiency is a condition where the adrenal glands do not produce adequate amounts of steroid hormones, affecting fluid and electrolyte balance.)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>SIADH<|>Tolvaptán is used to treat hyponatremia caused by SIADH by promoting the excretion of water<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>HIPO-NATREMIA<|>Hyponatremia can occur in patients receiving artificial nutrition due to fluid imbalances<|>5)\n##\n(\"relationship\"<|>FURST FORMULA<|>HIPO-NATREMIA<|>The Furst formula is used to assess sodium levels in patients with hyponatremia<|>6)\n##\n(\"relationship\"<|>FUROSEMIDA<|>HIPO-NATREMIA<|>Furosemide is used to manage fluid retention in patients with hyponatremia<|>7)\n##\n(\"relationship\"<|>HIPOALDOSTERONISMO<|>HIPO-NATREMIA<|>Hypoaldosteronism can lead to hyponatremia due to sodium loss<|>6)\n##\n(\"relationship\"<|>INSUFICIENCIA SUPRARRENAL<|>HIPO-NATREMIA<|>Adrenal insufficiency can cause hyponatremia due to inadequate hormone production affecting sodium balance<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: valorar la evolución de la urea y la creatina\n   con el descenso de la natremia: aumento (HipoNa\n   hipovolémica) y descenso (HipoNa hipervolémica).\n3) Historia clínica y estudio analítico de HipoNa\n   (iones-osmolalidad en plasma y en muestra aisla-\n   da de orina, cortisol basal y hormonas tiroideas).\n   En base a lo anterior, confirmar el tipo de HipoNa\n   y establecer su etiología: pérdidas digestivas, diu-\n   réticos, hipoaldosteronismo aislado, insuficiencia\n   suprarrenal primaria, elevación fisiológica de\n   ADH, SIADH, insuficiencia suprarrenal secunda-\n\n| Tabla 6. Tratamiento de la hiponatremia no grave asociada a SIADH tras la retirada de la nutrición artificial. |\n|-----------------------------------------------------------------------------------------------------------|\n| Terapia | Indicaciones | Precauciones |\n|---------|--------------|---------------|\n| Restricción hídrica | · Fórmula Furst (NaU + KU/NaS): <br> · < 0,5 (RH a 1 l); 0,5-1 (RH 0,5 l); <br> · > 1 (no respuesta RH) <br> · Capacidad de cumplimiento (medicación intravenosa, sueroterapia, suplementos orales) | · RH < 0,5 L disminuye la palatabilidad de la comida (evitar en pacientes desnutridos) |\n| Furosemida | · OsmU > 350 mOsm/kg <br> · SIADH transitorio | · Incrementar significativamente el consumo de sal para mantener la eficacia (con cuidado en HTA, monitorizar PA) <br> · Vigilar el potasio plasmático |\n| Tolvaptán | · Ausencia de respuesta a RH e incapacidad para su cumplimiento <br> · Ausencia de respuesta a furosemida <br> · OsmU < 350 mOsmol/kg y Furst > 1 <br> · SIADH crónico | · A su inicio, evitar la administración conjunta con otras terapias que eleven la natremia (furosemida, RH) |\n| Urea | · Mutación activadora del receptor V2 (sospechar ante la ausencia de respuesta a tolvaptán) | · Mala palatabilidad con inducción de la náusea (evitar en pacientes desnutridos) <br> · Riesgo de deshidratación e hipernatremia en pacientes sin capacidad para beber agua libremente (ancianos, pacientes institucionalizados, deterioro cognitivo, etc.) |\n\nHTA: hipertensión arterial; KU: potasio urinario; NaU: sodio urinario; NaS: sodio sérico; OsmU: osmolalidad urinaria;\nPA: presión arterial; RH: restricción hídrica; SIADH: síndrome de secreción inadecuada de ADH.\n---\nTema 51. Metabolismo hídrico en los pacientes con nutrición artificial... 813\n\n```mermaid\ngraph TD\n    A[INICIO de 7, 5 mg de TV con NaS basal (> 120 mmol/l)<br>+ 500 cc de SG 0,5% iv/24 h]\n    B[NaS a las 6 h]\n    C[Incremento<br>NaS ≤ 5 mmol/l]\n    D[1 l de SG al 5% a<br>pasar en 24 h<br>+<br>3 μg de DDAVP iv]\n    E[A las 24 h del inicio de TV: suspender perfusión de SG 5% y NaS<br>En función del incremento de NaS:<br>↑ ≤ 8 mmol/l: NaS < 135 mmol/l (TV 15 mg) y NaS ≥ 135 mmol/l (TV 7,5 mg)<br>↑ > 8 mmol/l: aplazar dosis de TV (7,5 mg) a las 48 h]\n    F[NaS a las 48 h : < 135 mmol/l ↑ dosis (15 a 30 y 7,5 a 15 mg/día) y si ≥ 135 mmol/l<br>(misma dosis que el día previo)]\n    \n    A --> B\n    B --> |↓ NaS / NO ↑ NaS| A\n    B --> |↑ NaS ≥ 5 mmol/l| D\n    B --> C\n    C --> E\n    D --> E\n    E --> F\n```\n\nFigura 4. Protocolo de inicio de tolvaptán en pacientes con SIADH y nutrición artificial.\nTV: tolvaptán, NaS: natremia sérica, SG: suero glucosado, DDAVP: desmopresina.\nAdaptado del algoritmo multidisplinar español de manejo del SIADH. Nefrología, 2014.\n\n| REPONER LA VOLEMIA |\n|---------------------|\n| HipoNa<br>HIPO-volémica | Nutrición enteral (NE)<\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}